SHH De Novo receives approval to initiate clinical trials in China with STING agonist DN015089
Source: Date:2021-07-27
Shanghai De Novo pharmatech Co., Ltd. has received Clinical Trial Application Approval on July 27, 2021 from the National Medical Products Administration (NMPA) to conduct clinical trials in China with DN015089.
沪公网安备 31011502005675号